Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin + cyclosporine is a combination of two active ingredients: curcumin, a natural polyphenol derived from turmeric with anti-inflammatory, antioxidant, and potential immunomodulatory properties, and cyclosporine, an immunosuppressant that inhibits calcineurin and T-cell activation. This combination has been investigated primarily in preclinical models for various indications, particularly autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Studies have focused on advanced formulations, such as nanoemulgels for topical delivery and bioadhesive pellets for colon targeting, aiming to exploit synergistic effects that allow reduced doses of each drug with comparable or superior efficacy to single-agent therapy. The mechanisms combine curcumin’s anti-inflammatory and antioxidant effects (modulating cytokines like TNF-alpha, IL-6, and NF-κB) with cyclosporine’s immunosuppression (primarily by blocking calcineurin and inhibiting T-lymphocyte activation)[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + cyclosporine.